

Ref. No: 337181021
From: Public
Date: 18/10/21
Subject: Management of patients with SLE &LN

REQUEST & RESPONSE

Please see below a Freedom of Information request made by OPEN Health on behalf of Otsuka Pharmaceuticals (U.K.) Ltd., a pharmaceutical company.

1. What guidelines or protocols do you refer to regarding the management of patients with:
 - a) Systemic lupus erythematosus (SLE) **EULAR AND BSR**
 - b) Lupus nephritis (LN) **EULAR AND BSR**
2. Please detail the number of patients that were admitted as an inpatient or day case in the last 12 months for the following primary diagnosis:

	Diagnosis (ICD10 code)
Patient number and care setting	Systemic lupus erythematosus with organ or system involvement (M321)
Inpatient admission	0
Day case	0

3. Do you refer patients within the ICD10 code M321 to another Trust? If you answered 'Yes', please detail which Trusts you refer patients to.
Royal Liverpool University Hospital
4. Is there a specific clinic for LN patients at your Trust?
No
5. Please complete the number of patients prescribed with the following products in the last 12 months within the ICD10 code Systemic lupus erythematosus with organ or system involvement (M321):

	Diagnosis (ICD10 code)
Product	Systemic lupus erythematosus with organ or system involvement (M321)
Azathioprine	0
Belimumab	0

Ciclosporin	0
Cyclophosphamide	0
Mycophenolate mofetil	0
Oral tacrolimus	0

6. Has a shared care agreement/arrangement been established between your institution and primary care for the treatment of lupus nephritis?
The shared care is for the medications

If you answered 'Yes', which of the following medicines can be prescribed within the shared care agreement?

	Azathioprine	Ciclosporin	Cyclophosphamide	Mycophenolate mofetil (MMF)	Oral tacrolimus
Yes/No	Yes	Yes	No	Yes	No

7. Has a shared care agreement/arrangement been established between your institution and a tertiary centre for the treatment of lupus nephritis? If so, please specify what medicines can be prescribed in secondary care within these shared care agreements.
No

8. What is the name of your local integrated care system?

Lupus isn't separately commissioned, and all Rheumatology service are currently on a block basis".

9. For the LN patient pathway, is care commissioned by:

Lupus isn't separately commissioned

	Activity	Block contract	Blended payment
Yes			
No			